Revised SPC: Xolair (omalizumab) solution for injection

SPC updated to reflect license extension for use as an add-on therapy with intranasal corticosteroids for severe chronic rhinosinusitis with nasal polyps in adults for whom therapy with intranasal corticosteroids do not provide adequate disease control.

Source:

electronic Medicines compendium